

## Anatara Lifesciences 4C & Q3 FY23 Activities Report

### Q3FY 2023 Highlights

- **Revised protocol for Irritable Bowel Syndrome (IBS) trial of “GaRP” 200 patient trial successfully implemented and enrolment on track.**
- **Recruitment for Stage 1 expected to be completed in 2Q 2023 with continued momentum in enrollment towards the required number of 90 Stage 1 patients.**
- **Trial is on budget with interim read-out of results anticipated mid Q3 CY2023.**
- **Shortfall of \$308K from Entitlement issue successfully placed in February 2023**
- **Licence agreement executed with specialty junior private healthcare company, Mucpharm Pty Ltd, to licence technology from Anatara for use in specific fields of interest, particularly mucin producing cancers and biofilms.**

MELBOURNE, 20 April 2023: Anatara Lifesciences (ASX:ANR or “the Company”), a developer of evidence-based solutions for gastrointestinal diseases in humans and animals, is pleased to provide an update on the Gastrointestinal ReProgramming(GaRP) trial for IBS.

### GaRP – Irritable Bowel Syndrome (IBS) - Trial Update

The Company is pleased to advise that the trial momentum and enrolment is now essentially consistent with the previous guidance and allowing for the April holiday periods. The total of enrolled participants has increased with good momentum building on the “approximately 50” reported in the March update (ASX release 10 March 2023). As per previous advice, we note there have been no significant tolerance or safety issues to date and that, with respect to the withdrawal consideration, one-third of participants are randomised to placebo.

The new “GaRP” trial criteria for IBS (Irritable Bowel Syndrome excluding only the constipation subset) has led to increased interest in participation and a higher enrolment rate. Apart from modifying the GaRP trial criteria, as previously advised, the Company engaged the ProPharma Group to act as the principal clinical research organisation towards the end of CY2022. Effectively Anatara has installed a new team and internal supervisory process for the ongoing trial.


The current recruitment rate is anticipated to result in the interim analysis becoming available in mid 3Q CY2023 when 90 participants remaining involved is reached, slightly later than previously indicated. The recruitment for Stage 1 is expected to be complete in 2Q2023. Importantly the budget has not been significantly impacted by this time variation.

The Company takes this opportunity to again thank the trial sites for the adjustments required and to confirm that the Royal Melbourne Hospital (RMH) continues to recruit strongly for the GaRP-IBS trial.

The GaRP IBS trial is powered to deliver results that will validate support claims. If successful, the high prevalence of digestive disorders requiring relief from both symptoms and the disease process, including irritable bowel syndrome (IBS), present a significant market opportunity for Anataara.

The commercial opportunity for non-prescription products for gastrointestinal disorders and IBS is US\$8 billion in the US.<sup>1</sup>

### GaRP-IBS Clinical Trial Design



### Mucpharm Pty Ltd licence agreement

On 10<sup>th</sup> March 2023, the Company announced an agreement with Mucpharm to licence technology from Anataara's portfolio for use in specific fields of interest, particularly mucin producing cancers and biofilms. The agreement provides Anataara with royalties on sales and sub-licensing.

Mucpharm is a specialised company focused on the treatment of mucin-containing and secreting conditions. It is developing the novel use of "BromAc", a combination of bromelain and acetylcysteine, in specific fields including cystic tumours.

### Ongoing corporate initiatives

In preparation for the GaRP interim trial results, Anataara is engaging with global pharma companies interested in expanding their portfolio of complementary medicines. The trial is garnering interest from global leaders in gastrointestinal health due to the strong evidence-based design of the GaRP trial and the potential for use of the product in other indications.

The Company continues to actively assess other opportunities in the healthcare space.

<sup>1</sup> <https://www.grandviewresearch.com/press-release/global-brain-health-supplements-market>

## Summary Q3 FY2023 cashflows

The Company's cash at the end of the quarter was \$1.17 million (31<sup>st</sup> December 2022: \$1.35 million). The Company announced on 21<sup>st</sup> February 2023 that the shortfall from the previous entitlement offer (prospectus 21<sup>st</sup> October 2022) had been placed in full to sophisticated and institutional investors raising an additional \$307,791.

Net cash used in operating activities during the quarter was \$0.42 million down from \$0.72 million from the previous quarter.

Aggregate payments to related parties and their associates during the quarter \$75,000 which includes directors' fees and superannuation.

## For more information please contact:

### Dr. David Brookes

Chair, Anantara Lifesciences Ltd

+61 (0) 411 712 579

[dbrookes@anantara.com](mailto:dbrookes@anantara.com)

### Dirk van Dissel

Candour Advisory – Investor Relations

+61 (0) 408 326 367

[dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

## About Anantara Lifesciences Ltd

Anantara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anantara is a life sciences company with expertise in developing products for human and animal health. Anantara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

### Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anantara Lifesciences Limited

Registered Office

Perks: Level 8 81 Flinders Street, Adelaide SA 5000 Australia

Email [info@anantara.com](mailto:info@anantara.com) | Website [anataralifesciences.com](http://anataralifesciences.com)



## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Anatara Lifesciences Ltd (ASX:ANR)

**ABN**

41 145 239 872

**Quarter ended ("current quarter")**

31 March 2023

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (9 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(172)	(785)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	(13)	(73)
(d) leased assets	-	(4)
(e) staff costs	(151)	(590)
(f) administration and corporate costs	(145)	(601)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	2	3
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	505
1.8 Other (provide details if material)	58	117
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(421)</b>	<b>(1,428)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	(2)
(d) investments	(50)	(50)
(e) intellectual property	-	-
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	50	50
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>-</b>	<b>(2)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	308	1,698
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(57)	(199)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	(4)	(16)
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>247</b>	<b>1,483</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	1,347	1,120
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(421)	(1,428)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	(2)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	247	1,483
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	<b>Cash and cash equivalents at end of period</b>	<b>1,173</b>	<b>1,173</b>

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	323	1,347
5.2	Call deposits	850	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>1,173</b>	<b>1,347</b>

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	75
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

Item 6.1 Reflects amounts paid to directors including director's fees, salaries, superannuation, bonuses and consulting fees (excluding reimbursements)

<b>7.</b>	<b>Financing facilities</b> <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	<b>Total financing facilities</b>	-	-
7.5	<b>Unused financing facilities available at quarter end</b>	-	-
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

<b>8.</b>	<b>Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1	Net cash from / (used in) operating activities (item 1.9)	(421)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,173
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	1,173
8.5	<b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	2.79
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A		
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A		
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A		
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 20 April 2023



Authorised by: David Brookes – Chair  
(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.